is glp 1 safe to take GLP-1 Agonists: Using Semaglutide, Tirzepatide, and Orforglipron for Weight Loss and Obesity GLP-1 Drugs for Weight Loss
Description
The company has completed a phase one trial in patients with diabetes and plans to present the data at a medical conference later this year, executives said during an earnings call in April
After propensity score matching, there was no significant difference found for the risk of oral steroid use (aOR: 0.81, 95% CI: 0.481.36), intravenous steroid use (aOR: 0.69, 95% CI: 0.291.61), the need to initiate advanced therapy (aOR: 1.03, 95% CI: 0.412.60), or the risk of any-cause emergency department visits (aOR: 0.92 (0.521.61) at one year between the semaglutide-treated and non-semaglutide-treated IBD patients
The JAMA Internal Medicine study found similar rates of GI adverse events between semaglutide and tirzepatide
The lowest commonly used starting dose is 0.5 mg administered once weekly
doi: 10.1530/EC-17-0015 24 GasbjergLSRasmussenRSLangbergLSstergaardFVestergaardMBAsmarAet al
